Tenaya Therapeutics (TNYA) Competitors $0.51 +0.04 (+7.37%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$0.50 -0.01 (-1.18%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. ACTU, CYBN, IPHA, MOLN, NBTX, LFVN, AARD, ACIU, TNGX, and DMACShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Actuate Therapeutics (ACTU), Cybin (CYBN), Innate Pharma (IPHA), Molecular Partners (MOLN), Nanobiotix (NBTX), LifeVantage (LFVN), Aardvark Therapeutics (AARD), AC Immune (ACIU), Tango Therapeutics (TNGX), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Actuate Therapeutics Cybin Innate Pharma Molecular Partners Nanobiotix LifeVantage Aardvark Therapeutics AC Immune Tango Therapeutics DiaMedica Therapeutics Tenaya Therapeutics (NASDAQ:TNYA) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking. Does the MarketBeat Community believe in TNYA or ACTU? Tenaya Therapeutics received 41 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Actuate Therapeutics an outperform vote while only 84.31% of users gave Tenaya Therapeutics an outperform vote. CompanyUnderperformOutperformTenaya TherapeuticsOutperform Votes4384.31% Underperform Votes815.69%Actuate TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes Is TNYA or ACTU more profitable? Actuate Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenaya TherapeuticsN/A -86.17% -71.14% Actuate Therapeutics N/A N/A N/A Do insiders & institutionals believe in TNYA or ACTU? 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 32.8% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 69.3% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to TNYA or ACTU? In the previous week, Tenaya Therapeutics had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for Tenaya Therapeutics and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.49 beat Tenaya Therapeutics' score of 0.36 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, TNYA or ACTU? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenaya TherapeuticsN/AN/A-$124.08M-$1.32-0.39Actuate TherapeuticsN/AN/A-$24.75MN/AN/A Do analysts prefer TNYA or ACTU? Tenaya Therapeutics currently has a consensus price target of $6.25, suggesting a potential upside of 1,125.49%. Actuate Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 115.79%. Given Tenaya Therapeutics' higher possible upside, equities research analysts plainly believe Tenaya Therapeutics is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryActuate Therapeutics beats Tenaya Therapeutics on 6 of the 11 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.67M$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.3530.0722.5918.54Price / SalesN/A494.82401.35103.29Price / CashN/A168.6838.1834.62Price / Book0.253.176.774.25Net Income-$124.08M-$72.35M$3.22B$248.18M7 Day Performance3.83%2.14%1.39%1.03%1 Month Performance-9.88%5.67%2.78%2.70%1 Year Performance-88.96%-23.57%15.85%4.05% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.7815 of 5 stars$0.51+7.4%$6.25+1,125.5%-89.1%$44.67MN/A-0.35110Short Interest ↓ACTUActuate TherapeuticsN/A$8.18+2.3%$20.00+144.5%N/A$159.77MN/A0.0010CYBNCybin1.5972 of 5 stars$7.43+1.1%$86.00+1,057.5%N/A$159.57MN/A-1.7050IPHAInnate Pharma2.5698 of 5 stars$1.90-3.6%$11.50+505.3%-11.7%$159.28M$12.63M0.00220Gap UpMOLNMolecular Partners2.4054 of 5 stars$3.91-1.5%$12.00+206.9%-3.1%$157.87M$4.97M-1.82180Gap UpHigh Trading VolumeNBTXNanobiotix1.9488 of 5 stars$3.32+0.9%$8.00+141.0%-44.8%$156.48M$-11,609,000.000.00100Positive NewsLFVNLifeVantage4.2047 of 5 stars$12.26-8.7%$30.50+148.8%+89.5%$153.88M$212.15M21.89260Positive NewsGap DownAARDAardvark TherapeuticsN/A$6.97-0.4%$31.50+351.9%N/A$151.22MN/A0.0018ACIUAC Immune2.4727 of 5 stars$1.48flat$12.00+710.8%-33.2%$148.61M$27.31M-3.22140Earnings ReportAnalyst ForecastNews CoveragePositive NewsTNGXTango Therapeutics2.3596 of 5 stars$1.37+6.2%$12.33+800.2%-80.6%$148.11M$42.07M-1.1690Upcoming EarningsNews CoveragePositive NewsGap DownDMACDiaMedica Therapeutics1.7026 of 5 stars$3.39-4.2%$8.00+136.0%+59.5%$145.28MN/A-6.0520Upcoming Earnings Related Companies and Tools Related Companies Actuate Therapeutics Competitors Cybin Competitors Innate Pharma Competitors Molecular Partners Competitors Nanobiotix Competitors LifeVantage Competitors Aardvark Therapeutics Competitors AC Immune Competitors Tango Therapeutics Competitors DiaMedica Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TNYA Stock Free TNYA Stock Alerts